| Item Type | Name |
|
Concept
|
Leukemia, Myeloid, Acute
|
|
Academic Article
|
Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval.
|
|
Academic Article
|
Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
|
|
Academic Article
|
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
|
|
Academic Article
|
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.
|
|
Academic Article
|
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.
|
|
Academic Article
|
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.
|
|
Academic Article
|
Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML.
|
|
Academic Article
|
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
|
|
Academic Article
|
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
|
|
Academic Article
|
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
|
|
Academic Article
|
Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?
|
|
Academic Article
|
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).
|
|
Academic Article
|
An integrated genomic approach to the assessment and treatment of acute myeloid leukemia.
|
|
Academic Article
|
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
|
|
Academic Article
|
Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia.
|
|
Academic Article
|
Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia.
|
|
Academic Article
|
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
|
|
Academic Article
|
G3139, a BCL-2 antisense oligo-nucleotide, in AML.
|
|
Academic Article
|
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.
|
|
Academic Article
|
A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.
|
|
Academic Article
|
Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia.
|
|
Academic Article
|
Expanded indications for allogeneic stem cell transplantation in patients with myeloid malignancies.
|
|
Academic Article
|
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
|
|
Academic Article
|
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.
|
|
Academic Article
|
Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia.
|
|
Academic Article
|
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.
|
|
Academic Article
|
MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia.
|
|
Academic Article
|
Minimal residual disease in acute myeloid leukemia--current status and future perspectives.
|
|
Academic Article
|
Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients.
|
|
Academic Article
|
Novel drug targets in acute leukemia.
|
|
Academic Article
|
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
|
|
Academic Article
|
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
|
|
Academic Article
|
Is it time to use minimal residual disease to stratify post-remission treatment for acute myeloid leukemia?
|
|
Academic Article
|
Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.
|
|
Academic Article
|
Neurocysticercosis Coincident with Acute Myeloid Leukemia: A Case Report.
|
|
Academic Article
|
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).
|
|
Academic Article
|
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
|
|
Academic Article
|
A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without VNP40101M in patients (pts) with first relapse of acute myeloid leukemia (AML).
|
|
Academic Article
|
Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: Impact of Care at Specialized Cancer Centers on Survival Outcome.
|
|
Academic Article
|
Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
|
|
Academic Article
|
Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML.
|
|
Academic Article
|
Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician.
|
|
Academic Article
|
Refractory Hypokalemia from Syndrome of Apparent Mineralocorticoid Excess on Low-Dose Posaconazole.
|
|
Academic Article
|
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
|
|
Academic Article
|
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
|
|
Academic Article
|
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.
|
|
Academic Article
|
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.
|
|
Academic Article
|
A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.
|
|
Academic Article
|
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001.
|
|
Academic Article
|
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).
|
|
Academic Article
|
Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.
|
|
Academic Article
|
Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.
|
|
Academic Article
|
Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance).
|
|
Academic Article
|
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.
|
|
Academic Article
|
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.
|
|
Academic Article
|
A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.
|
|
Academic Article
|
Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome.
|
|
Academic Article
|
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
|
|
Academic Article
|
Treatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologists.
|
|
Academic Article
|
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
|
|
Academic Article
|
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia.
|
|
Academic Article
|
Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia.
|
|
Academic Article
|
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
|
|
Academic Article
|
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).
|
|
Academic Article
|
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.
|
|
Academic Article
|
Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials.
|
|
Academic Article
|
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.
|
|
Academic Article
|
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
|
|
Academic Article
|
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.
|
|
Academic Article
|
Structural racism is a mediator of disparities in acute myeloid leukemia outcomes.
|
|
Academic Article
|
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors.
|
|
Academic Article
|
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
|
|
Academic Article
|
Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.
|
|
Academic Article
|
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
|
|
Academic Article
|
Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy.
|
|
Academic Article
|
Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study.
|
|
Academic Article
|
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.
|
|
Academic Article
|
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia.
|
|
Academic Article
|
Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study.
|
|
Academic Article
|
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
|
|
Academic Article
|
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
|
|
Academic Article
|
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
|
|
Academic Article
|
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.
|
|
Academic Article
|
Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia.
|
|
Academic Article
|
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model.
|
|
Academic Article
|
FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients.
|
|
Academic Article
|
Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia.
|
|
Academic Article
|
Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia.
|